20 articles
A completed exploratory trial evaluates whether a specialized compression garment can reduce discomfort and improve quality of life in pelvic lymphedema patients.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Phase 1 trial evaluates PF-06863135 (elranatamab) alone and with immunomodulatory agents to find safe dosing in heavily pretreated myeloma patients.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
MD Anderson researchers evaluated vemurafenib, cetuximab, and irinotecan together to find the optimal dose and safety profile for advanced solid tumors.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
A completed phase 2 trial tested nab-paclitaxel combined with the checkpoint inhibitor pembrolizumab in patients with advanced urothelial cancer who cannot tolerate cisplatin.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
A Swiss feasibility trial tests digital mindfulness-based cancer recovery, tracking psychosocial outcomes, medication use, and biological markers.
A phase I trial tests SD-101, nivolumab, and radiation together against metastatic pancreatic cancer that has stopped responding to chemo.
A completed phase 3 trial compared A+AVD versus ABVD for advanced classical Hodgkin lymphoma, testing whether replacing bleomycin with brentuximab vedotin improves outcomes.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
